CNTA vs. CAPR
CNTA (Centessa Pharmaceuticals Limited) and CAPR (Capricor Therapeutics, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, CNTA returned 12.71%/yr vs 42.20%/yr for CAPR. At a 0.15 correlation, their price movements are largely independent.
Performance
CNTA vs. CAPR - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, CNTA achieves a 58.74% return, which is significantly higher than CAPR's -9.36% return.
CNTA
- 1D
- 0.20%
- 1M
- 0.28%
- YTD
- 58.74%
- 6M
- 34.58%
- 1Y
- 233.05%
- 3Y*
- 104.97%
- 5Y*
- 12.71%
- 10Y*
- —
CAPR
- 1D
- -2.06%
- 1M
- -13.89%
- YTD
- -9.36%
- 6M
- -8.40%
- 1Y
- 83.84%
- 3Y*
- 77.22%
- 5Y*
- 42.20%
- 10Y*
- -2.03%
CNTA vs. CAPR - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
CNTA Centessa Pharmaceuticals Limited | 58.74% | 49.31% | 110.43% | 156.77% | -72.47% | -48.23% |
CAPR Capricor Therapeutics, Inc. | -9.36% | 109.13% | 182.21% | 26.68% | 31.74% | -22.69% |
Correlation
The correlation between CNTA and CAPR is 0.08, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.08 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.11 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.15 |
Correlation (All Time) Calculated using the full available price history since Jun 1, 2021 | 0.15 |
Fundamentals
CNTA:
-$1.81
CAPR:
-$2.32
CNTA:
$15.00M
CAPR:
$0.00
CNTA:
$15.00M
CAPR:
-$42.41M
CNTA:
-$227.27M
CAPR:
-$117.24M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
CNTA vs. CAPR — Risk / Return Rank
CNTA
CAPR
CNTA vs. CAPR - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Centessa Pharmaceuticals Limited (CNTA) and Capricor Therapeutics, Inc. (CAPR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| CNTA | CAPR | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +3.32 | ||
| Sortino ratioReturn per unit of downside risk | +0.83 | ||
| Omega ratioGain probability vs. loss probability | 1.69 | 1.59 | +0.10 |
| Calmar ratioReturn relative to maximum drawdown | 8.90 | 1.26 | +7.64 |
| Martin ratioReturn relative to average drawdown | 24.63 | 2.38 | +22.25 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| CNTA | CAPR | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 3.54 | 0.22 | +3.32 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.18 | 0.22 | -0.05 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | -0.01 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.18 | -0.08 | +0.26 |
Drawdowns
CNTA vs. CAPR - Drawdown Comparison
The maximum CNTA drawdown since its inception was -88.19%, smaller than the maximum CAPR drawdown of -99.97%. Use the drawdown chart below to compare losses from any high point for CNTA and CAPR.
Loading charts...
Drawdown Indicators
| CNTA | CAPR | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -88.19% | -99.97% | +11.78% |
Max Drawdown (1Y)Largest decline over 1 year | -26.38% | -67.00% | +40.62% |
Max Drawdown (3Y)Largest decline over 3 years | -43.72% | -79.08% | +35.36% |
Max Drawdown (5Y)Largest decline over 5 years | -88.19% | -79.08% | -9.11% |
Max Drawdown (10Y)Largest decline over 10 years | — | -98.02% | — |
Current DrawdownCurrent decline from peak | -0.50% | -99.20% | +98.70% |
Average DrawdownAverage peak-to-trough decline | -51.99% | -90.24% | +38.25% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.51% | 35.96% | -26.45% |
Volatility
CNTA vs. CAPR - Volatility Comparison
The current volatility for Centessa Pharmaceuticals Limited (CNTA) is 0.72%, while Capricor Therapeutics, Inc. (CAPR) has a volatility of 18.21%. This indicates that CNTA experiences smaller price fluctuations and is considered to be less risky than CAPR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| CNTA | CAPR | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 0.72% | 18.21% | -17.49% |
Volatility (6M)Calculated over the trailing 6-month period | 44.27% | 50.01% | -5.74% |
Volatility (1Y)Calculated over the trailing 1-year period | 66.48% | 385.34% | -318.86% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 72.09% | 190.06% | -117.97% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 72.30% | 179.86% | -107.56% |
Dividends
CNTA vs. CAPR - Dividend Comparison
Neither CNTA nor CAPR has paid dividends to shareholders.
Financials
CNTA vs. CAPR - Financials Comparison
This section allows you to compare key financial metrics between Centessa Pharmaceuticals Limited and Capricor Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
CNTA and CAPR have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
CAPR has higher volatility (18.21%) compared to CNTA (0.72%). In terms of maximum drawdown, CNTA dropped -88.19% vs CAPR's -99.97%.
CNTA currently has the higher Sharpe Ratio (3.54 vs 0.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for CNTA and CAPR
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer